On Tuesday, Rodman & Renshaw initiated coverage on shares of NASDAQ:QNCX, Quince Therapeutics Inc., with a Buy rating and a price target of $11.00. The new coverage highlights Quince's innovative approach to leveraging corticosteroid treatments while mitigating the associated side effects.
Quince Therapeutics has developed a proprietary technology platform called AIDE, which stands for autologous intracellular drug encapsulation. This platform is designed to deliver the benefits of corticosteroids, such as their strong anti-inflammatory effects, while reducing or eliminating the significant side effects that often accompany long-term use.
The company's leading therapeutic candidate, EryDex, utilizes this technology by encapsulating dexamethasone sodium phosphate within a patient's own red blood cells. This method is intended to treat rare diseases by enabling a unique biodistribution, which could allow the drug to be released slowly as it travels through the body, potentially increasing the efficacy and safety of the treatment.
Quince is currently conducting a pivotal trial for Ataxia-telangiectasia (A-T), a rare genetic disorder characterized by a variety of symptoms, including cerebellar ataxia and a predisposition to cancer. The trial is considered de-risked based on previous studies that showed significant benefits to A-T patients, particularly those aged 6-9 years.
With an estimated 10,000 diagnosed A-T patients in the United States and five key European countries, and considering orphan drug pricing ranging from $350,000 to $400,000 per year, EryDex has the potential to become a blockbuster treatment. Beyond A-T, Quince aims to explore the use of EryDex for other rare diseases where steroids are beneficial but currently limited due to toxicity concerns.
In other recent news, Quince Therapeutics has been making significant strides in the biotech industry. The company's lead product, EryDex, has been recognized for its innovative approach in treating Ataxia-Telangiectasia (A-T), a rare genetic disorder. EF Hutton recently initiated coverage on Quince Therapeutics with a Buy rating, expressing optimism about EryDex's potential.
Quince Therapeutics has released data from its Phase 3 ATTeST clinical trial, indicating a favorable safety profile and a positive effect in a subset of patients, specifically children aged six to nine. The company continues its NEAT study, another Phase 3 trial, with results expected in the fourth quarter of 2025.
However, the company faces potential delisting from The Nasdaq Global Select Market due to non-compliance with the minimum bid price requirement. Quince has until December 17, 2024, to regain compliance, but the ability to meet Nasdaq's continued listing criteria or secure an extension remains uncertain.
In a positive development, the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Quince's EryDex System, marking a significant regulatory milestone for the company. These are among the recent developments surrounding Quince Therapeutics, as the company continues to innovate and navigate regulatory challenges.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Quince Therapeutics' financial position and market performance. The company's market capitalization stands at $42.91 million, reflecting its current valuation in the biotech sector. Notably, Quince has demonstrated strong short-term market performance, with a 33.64% price return over the last three months and a 23.95% return in the past month.
These positive market trends align with the optimistic outlook presented by Rodman & Renshaw's Buy rating and $11.00 price target. However, investors should be aware of some financial challenges. An InvestingPro Tip indicates that Quince is "quickly burning through cash," which is not uncommon for biotech companies in the development stage but warrants attention.
Another relevant InvestingPro Tip reveals that Quince "holds more cash than debt on its balance sheet," potentially providing some financial flexibility as it progresses with its pivotal trial for EryDex. This could be crucial for supporting the company's research and development efforts in the competitive rare disease treatment market.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for Quince Therapeutics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.